Valuation: Ipsen S.A.

Market Cap 13.54B 15.81B 12.63B 11.59B 21.78B 1,513B 22.21B 150B 58.41B 758B 59.36B 58.07B 2,510B P/E 2026 *
13.7x
P/E 2027 * 14x
Enterprise Value 12.3B 14.36B 11.47B 10.53B 19.78B 1,374B 20.17B 136B 53.07B 689B 53.93B 52.76B 2,280B EV / Sales 2026 *
2.71x
EV / Sales 2027 * 2.42x
Free-Float
40.65%
Yield 2026 *
0.93%
Yield 2027 * 0.93%
1 day-1.18%
1 week+7.26%
Current month-2.88%
1 month+3.44%
3 months+4.88%
6 months+4.95%
Current year+38.26%
1 week 153.4
Extreme 153.4
165.5
1 month 153.4
Extreme 153.4
170.7
Current year 116.4
Extreme 116.4
173.1
1 year 110.6
Extreme 110.6
173.1
3 years 88.3
Extreme 88.3
173.1
5 years 77.62
Extreme 77.62
173.1
10 years 66.65
Extreme 66.65
173.1
Manager TitleAgeSince
Chief Executive Officer 59 01/07/2020
Chief Executive Officer 57 01/01/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 30/08/2005
Chairman 68 22/11/2010
Director/Board Member 69 01/06/2012
Change 5-day change 1-year change 3-year change Capi.($)
-1.15%+7.26% - - 15.78B
-1.33%+4.63%+79.32%+129.98% 1,141B
-1.12%+3.48%+51.64%+62.05% 659B
-0.47%+5.74%+26.80%+76.61% 470B
+1.20%+2.62%+41.69%+46.21% 366B
-0.61%+2.10%+23.43%+40.38% 302B
+0.32%+3.25%+0.94%+13.25% 254B
-1.74%+4.17%+46.83%+66.96% 239B
-1.10%-0.70%-14.31%-53.04% 207B
-1.37%+5.47%+22.72%+91.86% 183B
Average -0.73%+4.10%+31.01%+52.70% 424.55B
Weighted average by Cap. -0.75%+4.31%+45.04%+73.17%

Financials

2026 *2027 *
Net sales 4.54B 5.31B 4.24B 3.89B 7.31B 508B 7.45B 50.29B 19.6B 254B 19.92B 19.49B 842B 4.64B 5.42B 4.33B 3.97B 7.46B 518B 7.61B 51.32B 20.01B 260B 20.34B 19.89B 860B
Net income 1.01B 1.18B 943M 865M 1.63B 113B 1.66B 11.19B 4.36B 56.61B 4.43B 4.34B 187B 985M 1.15B 919M 844M 1.59B 110B 1.62B 10.91B 4.25B 55.19B 4.32B 4.23B 183B
Net Debt -1.24B -1.45B -1.16B -1.06B -1.99B -138B -2.03B -13.7B -5.34B -69.34B -5.43B -5.31B -230B -2.3B -2.69B -2.15B -1.97B -3.7B -257B -3.77B -25.45B -9.92B -129B -10.08B -9.86B -426B
Logo Ipsen S.A.
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change
19/08/26 165.50 +1.29%
18/08/26 €163.40 +2.13%
17/08/26 €160.00 +4.30%
14/08/26 €153.40 -1.22%
13/08/26 €155.30 +0.65%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
165.10EUR
Average target price
167.07EUR
Spread / Average Target
+1.19%

Quarterly revenue - Rate of surprise